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1. Introduction 
As the conduit for oxygen, nutrients and waste products, the 
vascular system that supports a tumour is a rational target for 
anticancer therapy.  Two strategies have emerged for the clinical 
exploitation of this principle,2 the first being the use of 
angiogenesis inhibitors, which target growth factors so as to 
prevent the formation of new vasculature.3  The pioneering 
example of this approach is the monoclonal antibody 
bevacizumab (Avastin).4  The second strategy is to employ 
vascular disrupting agents (VDAs) to attack newly-formed 
tumour vasculature, which is structurally flawed by excessive 
branching, uneven diameter, shunts, etc., and more sensitive than 
normal host vasculature to small molecules that perturb the 
morphology and functionality (migration, adhesion, proliferation) 
of the nascent endothelial cells.5  Microtubules play a prominent 
role in maintaining the physical structure of these cells, and most 
VDAs are tubulin-binding agents that undermine tubulin-
microtubule dynamics at sub-micromolar concentrations.   
In seeking new structures for screening as VDAs, we 
identified the dibenz[c,e]oxepinol 1 as a potent inhibitor of 
microtubule assembly and a possible lead in this context.1  A 
crystallographic analysis of the dibenz[c,e]oxepine nucleus6 led 
us to conclude that it was well equipped to serve in this capacity 
by virtue of its ability to match, in both degree and sense, the 
conformational helicity of colchicine 2, which is crucial to the 
latter's ability to bind to tubulin,7 and by analogy with N-
acetylcolchinol methyl ether (NCME) 3, whose binding to 
tubulin is strong but rapidly reversible, i.e. compatible with drug-
like pharmacokinetics.8  Indeed the parent phenol N-
acetylcolchinol (NAC) 4 was developed as a VDA in the form of 
the phosphate prodrug ZD6126 5, although the project was 
curtailed following the observation of adverse cardiac events in 
phase I clinical trials.9,10  Various alternative structures have 
progressed to clinical trials as VDAs,11 the best known being 
combretastatin A-4 (CA-4) 6 which, as the phosphate prodrug 7 
(CA-4P; fosbretabulin; Zybrestat), has featured in human trials as 
a single agent12 and in combinations with cytotoxic agents 
(paclitaxel, carboplatin), radiotherapy, or the antiangiogenic 
agent, bevacizumab.13  Other stilbenes in development include 
combretastatin A-1 (CA-1) 8, in the form of the prodrug 9 
(OXi4503),14 and AVE8062 10 (ombrabulin).15  The benzofuran 
11 (BNC105),16 the diketopiperazine 12 (plinabulin),17 the 
pyrimidine 1318 and the chromene 14 (crolibulin)19 have also 
progressed to clinical trials.  Despite their structural diversity, all 
of these candidate VDAs bind to tubulin at, or close to, the same 
site as colchicine 2, which is located at the interface of the two 
subunits of the α,β-tubulin heterodimer.20   
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5,7-Dihydro-3,9,10,11-tetramethoxybenz[c,e]oxepin-4-ol 1, prepared from a dibenzyl ether 
precursor via Pd-catalysed intramolecular direct arylation, possesses broad-spectrum in 
vitro cytotoxicity towards various tumour cell lines, and induces vascular shutdown, 
necrosis and growth delay in tumour xenografts in mice at sub-toxic doses.  The biological 
properties of 1 and related compounds can be attributed to their ability to inhibit 
microtubule assembly at the micromolar level, by binding reversibly to the same site of the 
tubulin αβ-heterodimer as colchicine 2 and the allocolchinol, N-acetylcolchinol 4. 
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While the colchicine binding site of tubulin can accommodate 
a range of structures, it is not an ideal target for therapeutics.  
Agents that inhibit microtubule assembly by binding to this site 
are associated with dose-limiting cardiac events (ischemia, 
infarction, ventricular tachycardia),21 and this has been attributed 
to cell-cycle arrest in the endothelial cells of the myocardium.22  
Zybrestat 7 shows neurotoxic and cardiac effects (prolonged QT 
interval), and clinical trial protocols include measures to 
counteract hypertension and cardiac ischemia.13a,23  Prolonged 
QT interval is also observed with OXi4503 914 and CYT997 
13.18a  Cardiotoxicity is thus a generic issue with tubulin-
targeting VDAs, highlighting the need for finely-balanced 
therapeutics that are not compromised by this problem.24 
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The dibenz[c,e]oxepine pharmacophore is easily accessible1,25 
and potentially tunable with respect to binding, metabolic and 
transport characteristics.26  In this paper we describe new routes 
to the lead structure 1 and its biological evaluation as a VDA, 
along with the analogues 15–20.  The results show that in human 
tumour xenografts in mice, the prodrugs 15 (derived from 1) and 
21 (from the clinically tested VDA 5) are similar in their ability 
to induce necrosis, and that 1 inhibits tumour growth in vivo. 
 
 
 
2. Results and discussion 
2.1. Synthesis of materials 
Our original route to the key structure 1, based on a 
conventional Ullmann biaryl synthesis,1 was improved by 
switching to iodoarene cross-coupling partners (Scheme 1).  The 
C-ring precursor 23 was conveniently prepared by direct 
iodination of o-vanillin mesylate 22 using iodine and periodic 
acid,27 and the same method provided the A-ring precursor 24 
from 3,4,5-trimethoxybenzaldehyde.  The outcome of the 
Ullmann coupling of 23 and 24 was strongly dependent on the 
reaction conditions, but guided by the painstaking analysis of this 
type of reaction by Brown and coworkers,28 we obtained 
acceptable yields of 25 using a solvent-free 3:1 mixture of the 
two components, a 5-fold excess of Cu powder, and careful 
control of the reaction time and temperature.  Ring-closure of the 
diol 26 to 27 was induced with aq. HBr, and the methanesulfonyl 
protecting group was cleanly removed from 27, to give 1, using a 
modified version of Carreira's method.29  
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Scheme 1. Improved Ullmann cross-coupling route to 1. 
 
We also developed a potentially more versatile approach to 1 
featuring a Pd-catalysed intramolecular direct arylation (IDA) 
reaction as the cyclisation step.  This strategy called for the 
construction of a dibenzyl ether bearing the latent A- and C-ring 
substituents of the target compound, together with a single 
halogen atom to mediate the metalation step.  To prepare such a 
precursor for 1, the MOM-protected aldehyde 29 was reduced to 
the alcohol 30, which was then alkylated using 3,4,5-
trimethoxybenzyl bromide 31 (Scheme 2).  The resulting ether 32 
was subjected to the IDA cyclisation conditions first described by 
Fagnou and coworkers30,31 and adapted by us for the preparation 
of dibenz[c,e]azepines.32  Chromatography of the product gave 
the desired heterocycle 34 in moderate yield, confirming that this 
is a viable approach to dibenz[c,e]oxepines.  Subsequent removal 
of the MOM group from 34 using aq. HCl completed the new 
route to the target 1. 
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Scheme 2. Intramolecular direct arylation route to 1. 
 
In seeking a water-soluble version of the dibenzoxepinol 1, we 
used a conventional reaction sequence33 to prepare the disodium 
phosphate 15 via the intermediates 35 and 36.  Mixing the 
dihydrogen phosphate 36 with two molar equivalents of freshly 
prepared sodium methoxide in methanol, followed by 
evaporation and drying in vacuo, provided the disodium salt 15 
as white powder.  Although essentially homogeneous by 1H, 13C 
and 31P NMR spectroscopy, this material proved to be 
hygroscopic, and microanalytical samples always retained small 
amounts of water and methanol. 
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The dibenzoxepinol 1 was also converted into the derived 
triflate 18 by conventional means.  The amine 20 was acquired in 
three steps from the biaryl dialdehyde 37, which proved 
accessible via an Ullmann cross-coupling reaction.  Subsequent 
reduction and cyclisation gave the nitro compound 19, which was 
transformed into the amine 20 by catalytic hydrogenation. 
 
 
 
2.2. Biological evaluation 
2 .2 .1 .  Inhib i t ion  of  micro tubule  assembly  and  in  
v i t ro  an t ipro l i fera t ive  ac t iv i ty  
Dibenzoxepines were routinely screened for their ability to 
inhibit microtubule assembly34,35 and for growth inhibitory 
activity (IC50) against the K562 human chronic myelogenous 
leukaemia cell line.36  Both of these assays are routinely used for 
evaluating test compounds and provide a useful comparison with 
benchmarks such as colchicine 2 and CA-4 6.  The results (Table 
1) show that the ability of the phenolic compound 1 to inhibit 
microtubule assembly is matched by the phosphate 15 (entry 6), 
with the latter also showing sub-nanomolar IC50 values in the 
K562 assay.  The activity shown by the triflate 18 (entry 9) is 
also noteworthy, and is consistent with prodrug behaviour. 
 
Table 1.  Activities (IC50) of compounds in the microtubule 
assembly and K562 in vitro cytotoxicity assays. 
 
  Tubulin assembly K562 assay 
Entry Compound IC50 µMa,b IC50 nMc,d 
1e 1 2.2 34 
2 2 2.0 19 
3 3 0.7f –g 
4 6 1.3 1.0 
5 7 0.9 0.72 
6 15 1.4 0.23 
7 16 7.4 110 
8 17 >10 85 
9 18 15 0.25 
10 19 >10 16 
11 20 >10 10 
aConcentration required for 50% inhibition of tubulin assembly. 
bEntries in this column are corrected for variations in the value for 6, which 
was used as a reference for assay batches. 
cConcentration that inhibits the growth of K562 cell line by 50% after 
incubation for 5 days.  Each drug concentration was tested in triplicate, and 
the standard error of each value is <10%. 
dEntries in this column are normalised to the value for 6, which varied over 
the range 1.2–3.0 between batches. 
eValues from ref. 1.  
fValue from ref. 37.  
gNot determined. 
 
2 .2 .2 .  In  v i tro  screen ing  aga ins t  NCI-60  ce l l  l ines  
The dibenzoxepines 1 and 15–17 were evaluated in the US 
National Cancer Institute (NCI) anticancer drug screen against 
the NCI-60 panel of human tumour cell lines.38,39  The sixty cell 
lines of this panel are organised by disease type, and test data 
relating to both the levels and the patterns of activity across the 
panel can be instructive.  Some of the results of the NCI-60 five-
dose assay of the dibenzoxepines are shown in Table 2.  
Compounds 1 and 16 reach similar levels in their inhibitory 
effects, each with more than twenty instances in which the GI50 
value is below 100 nM, whereas 15 and 17 register this level only 
with the MDA-MB-435 (melanoma) cell line.   
 
Table 2.  In vitro cell growth inhibition data for various 
dibenzoxepines against the NCI-60 panel of human cancer 
cell lines. 
 
  Cell growth inhibition (GI50, µM)a,b,c 
Panel Cell line 1 15 16 17 
Leukaemia CCRF-CEM 0.04 0.29 0.08 0.35 
 HL-60(TB) 0.03 0.32 0.04 0.39 
 K-562 0.04 0.28 0.04 0.21 
 MOLT-4 0.06 0.40 0.09 0.47 
 SR 0.04 0.19 0.04 0.17 
Non-small 
cell lung NCI-H522 0.04 0.30 0.28 0.39 
Colon HCT-116 0.32 0.43 0.05 0.37 
 HCT-15 0.08 0.44 0.08 0.48 
 KM12 0.05 0.30 0.05 0.36 
 SW-620 0.05 0.40 0.05 0.40 
CNS SF-268 0.09 0.79 0.46 1.32 
 SF-295 0.27 0.32 0.06 0.33 
 SF-539 0.05 0.33 0.16 0.35 
 SNB-19 0.14 0.51 0.98 0.68 
 SNB-75 0.07 0.54 0.09 0.46 
 U251 0.30 0.48 0.10 0.48 
Melanoma LOXIMVI 0.08 0.66 0.21 0.87 
 M14 0.05 0.27 0.05 0.23 
 MALME-3M ND 2.51 >100 >100 
 MDA-MB-435 0.03 0.04 0.03 0.05 
 SK-MEL-2 0.26 5.37 0.10 0.56 
 SK-MEL-28 1.58 0.89 0.08 ND 
 SK-MEL-5 0.04 0.26 0.03 0.21 
 UACC-62 1.00 5.50 0.08 0.79 
Ovarian NCI/ADR-RES 0.05 0.28 0.07 0.36 
 OVCAR-3 0.21 0.28 0.05 0.25 
 SK-OV-3 0.07 0.40 0.13 0.47 
Renal RXF393 0.04 0.21 0.08 0.20 
Prostate DU-145 0.06 0.39 0.18 0.37 
Breast BT-549 0.26 2.24 0.20 0.54 
 HS578T 0.04 0.24 0.24 0.43 
 MCF7 0.07 0.40 0.04 0.40 
 MDA-MB-468 0.22 1.15 0.03 0.17 
aGI50: concentration required for 50% cell growth inhibition.  
bOnly the cell-lines featuring one GI50 value below 100 nM are 
included in this table; see Supplementary Material for the full data 
set. 
cShading is applied to values below 100 nM; ND = not determined. 
 
 
 
The results with the human colorectal tumour cell line HCT-
15, which is known to express multidrug resistance protein (P-
glycoprotein),40 implies that the inhibitory properties of 1 and 16 
are not unduly affected by this efflux pump, which can 
undermine the effects of tubulin-targeting anticancer agents.41  
The NCI-60 mean GI50 values for 1 and 16 are similar (ca. 0.3 
µM), which compares to 0.04 µM for NCME 3. 
The NCI-60 screening results from the dibenzoxepines 1 and 
15–17, together with the public data for the colchicinoids 2–4 
and the stilbenes 6 and 7, were analysed using the matrix 
COMPARE algorithm.42  In this type of analysis, the activity 
profile of a 'seed' compound against the NCI-60 cell lines can be 
compared to that of any 'target' compound in the same database, 
with the COMPARE algorithm being used to generate a series of 
correlation coefficients (Table 3).  Compounds that exert their 
inhibitory effects by similar mechanisms of action can produce 
similar patterns of differential antiproliferative data, and the 
coefficients within the dibenzoxepine matrix (Table 3a) provide a 
reasonable case for the mechanistic correlation of this group of 
compounds, the borderline case being 16.  However, the extent to 
which this correlation is based on interaction with tubulin 
remains unclear, as is illustrated by the second section of results 
obtained with 2–4, 6 and 7 (Table 3b).  Matrix COMPARE 
coefficients (r values) less than 0.6 are of questionable 
significance,43,44 and there is considerable variation in the 
coefficient values across the whole matrix, ranging from notable 
homology (2 with 3; 3 with 6; 6 with 7) to almost complete 
disparity with N-acetylcolchinol 4, which in turn shows a modest 
correlation with 16.  Taken together, these results provide a 
reminder that the relationship between cytotoxicity (or 
cytostaticity) and the ability to shutdown vasculature remains 
obscure. 
Using the standard COMPARE protocol, the antiproliferative 
activity profiles of 1 and 15–17 were compared with those of the 
NCI standard agents collection of anticancer agents.45  This 
analysis, which can be used to identify the cellular targets of 
antitumour agents,44,46 was extended to include compounds 2–4, 
6 and 7 as the seeds (Table 3c).  The observed correlation of 15 
with maytansine and vincristine, which are known to target 
microtubule formation,47 provides further evidence that, as 
intended, the biological target of the dibenzoxepines is tubulin. 
 Table 3.  Results of COMPARE analyses involving the dibenzoxepines 1 and 15–17. (a) Matrix COMPARE data for the 
dibenzoxepines. (b) Standard COMPARE data for colchicinoids 2–4 and stilbenes 6 and 7. (c) Correlations from a standard 
COMPARE analysis of dibenzoxepines with the NCI standard agent database.a,b 
 
 Target Seed vector 
 vector 1 15 16 17 2 3 4 6 7 
a 
1  0.81 0.84 0.79      
15 0.81  0.66 0.73      
16 0.84 0.66  0.86      
17 0.79 0.73 0.87       
b 
2 colchicine 0.50 0.50 0.53 0.52  0.74 0.22 0.51 0.49 
3 NCME 0.43 0.48 0.42 0.45 0.74  0.02 0.71 0.58 
4 NAC 0.44 0.33 0.62 0.45 0.22 0.02  −0.01 0.12 
6 CA-4 0.40 0.43 0.31 0.31 0.51 0.71 −0.01  0.77 
7 CA-4P 0.58 0.53 0.40 0.38 0.49 0.58 0.12 0.77  
c 
maytansine 0.51 0.56 0.54 0.56 0.76 0.87 0.47 0.67 0.45 
vincristine 0.57 0.62 0.53 0.56 0.78 0.81 0.41 0.58 0.50 
paclitaxel 0.51 0.45 0.49 0.60 0.54 0.36 0.49 – – 
rhizoxin 0.43 0.45 0.45 0.52 0.74 0.83 0.38 0.64 0.59 
vinblastine 0.43 0.50 0.47 0.48 0.75 0.89 0.29 0.64 0.44 
aMatrix (r) values are Pearson's correlation coefficients,38 based on a comparison of the NCI GI50 mean graphs for each compound; see Supplementary Material 
for full search parameters and results. 
bShading is arbitrarily applied to r values ≥0.55.  NCI descriptors: 2, NSC 757; 3, NSC 51046; 4, NSC 51045; 6, 613729; 7, NSC 645646; maytansine, NSC 
153858; vincristine, NSC 67574; paclitaxel, NSC 125973; rhizoxin, NSC 332598; vinblastine, NSC 49842. 
 
 
2 .2 .3 .  In  v ivo  an t ivascular  e f fec ts  o f  15  
Given its close structural analogy and progress to clinical 
trials, we selected the erstwhile drug candidate 5,9,48 in the 
form of its disodium salt 21, as a benchmark for assessing the 
ability of 15 to function as a VDA at levels beneath the 
maximum tolerated dose (MTD).  In a side-by-side single-dose 
study, seven groups of athymic nude mice (n=3 per group) 
bearing subcutaneous DLD-1 human colon adenocarcinoma 
xenografts were used to assess the effects of treatment with the 
test compounds 15 and 21 on the functional vasculature in 
tumours.  Once an established tumour vascular network was in 
place, mice were treated with a single intravenous dose (400 
mg/kg) of 15 or 21 (three groups per compound).  The results 
(Figure 1) provided a clear demonstration of the vascular 
shutdown induced by both compounds, peaking ca. one hour 
after the administration of the compound.  This state persisted 
throughout the 24-h study period for 21, whereas for 15 some 
recovery of vasculature was evident from 4 h post dose.   
The extent of tumour necrosis (Figure 2) was only seen to 
be different to the control at 24 hours post dose for both 
compounds, which is consistent with the time delay expected 
for necrosis to occur following loss of blood supply to the 
tumour cells.  The ability of the dibenzoxepine 15 to target 
experimental tumours is clearly evident, and parallels that of 
the related allocolchinol 21.   
Representative images from the functional vasculature and 
necrosis studies are provided in Figures 3 and 4 respectively. 
 
 
15
O
MeO
MeO
OMe
OMe
OPO3Na2
21
MeO
MeO
OMe
OPO3Na2
NHAc
control 1 h 4 h 24 h 1 h 4 h 24 h
%
 F
un
ct
io
na
l v
as
cu
la
tu
re
200
150
100
50
0
 
Figure 1.  Chart showing the time-dependent vascular shutdown of DLD-1 human colon adenocarcinoma xenografts in mice following a single intravenous 
dose (400 mg/kg) of 15 or 21 (mean ± SEM). 
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Figure 2.  Chart showing the quantification of tumour necrosis in DLD-1 human colon adenocarcinoma xenografts in mice following a single intravenous 
dose (400 mg/kg) of 15 or 21 (mean ± SD). 
 
Figure 3.  Representative images of DLD-1 human colon adenocarcinoma xenografts showing remaining functional vasculature using Hoechst 33342 
staining, following a single intravenous dose of 15 or 21 at 400 mg kg–1 at 1, 4 and 24 h post dose. 
 
 
Figure 4.  Representative images of haematoxylin- and eosin-stained DLD-1 human colon adenocarcinoma xenografts following a single intravenous dose of 
15 or 21 at 400 mg kg–1 at 1, 4 and 24 h post dose. 
 
2 .2 .4 .  In  v ivo  an t i tumour  e f fec ts  o f  1  
The potential of the benz[c,e]oxepine series as a source of 
in vivo antitumour agents was investigated using benzoxepinol 
1 in a two-dose study with mice bearing subcutaneous Calu-6 
lung tumour xenografts.  Calu-6 is well vascularised and has 
been used previously to study VDAs.49  Guidelines for the 
MTDs of various dibenzoxepines in mice were obtained by 
monitoring the effects of a single exposure on body weight 
over two weeks, and a limit of 270 mg/kg was set for 1 (Figure 
5a).  The antitumour properties of 1 were then monitored in a 
10-day study of mice with implanted Calu-6 xenografts.  Doses 
of one-quarter or one-half of the nominal MTD on days 1 and 
5 had approximately the same inhibiting effect on tumour 
growth for 24 h, with regrowth then resuming at the original 
rate (Figure 5b).  The dibenzoxepine 1 was thus demonstrated 
to be carcinostatic, inducing a growth delay in the 
experimental tumours at one-quarter of the nominal MTD, and 
was well tolerated in tumour-bearing mice. 
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Figure 5.  The dibenzoxepine 1 is well tolerated in tumour-bearing mice and induces a highly significant growth delay in subcutaneous Calu-6 lung tumour 
xenografts.  (a) shows average mouse weight, (b) shows average tumour volume (n=5 control, n=6 treated mice per group).  Arrows indicate administration of 1 
at the noted dosages.  The doses 67.5 mg/kg and 135 mg/kg equate to 0.25 and 0.5 MTD respectively.  Compound 1 was dosed in 5% DMSO in peanut oil. 
 2 .2 .5 .  Mechanis t ic  cons idera t ions  
The tubulin-binding capability of the dibenzoxepine 1 is 
consistent with its structural analogy with colchicine.  The 1SA0 
crystal structure provides a detailed picture of the interaction of 
N-deacetyl-N-(2-mercaptoacetyl)colchicine (DAMA-colchicine) 
38 with the interchain boundary of the αβ-tubulin heterodimer,20 
which accounts for the disruptive effect of colchicinoids on the 
finely-poised dynamics of this interface.  We speculate that, 
while chemically distinct from colchicine 2 and the 
combretastatins such as 6, the dibenzoxepine 1 binds to the αβ-
tubulin heterodimer at the same location and in a similar 
manner.1  Our mechanistic model for this interaction, shown in 
Figure 6a, assumes the favourable locations of H-bond donor and 
acceptor sites a and b that can anchor the C-ring of the β-tubulin-
bound ligand to the nearby α-tubulin.  It is generally assumed 
that β -Cys241 provides colchicinoids with the third anchor c, 
although the case for this being solely through H-bonding is less 
compelling, as the trimethoxy motif is not indispensible.50   
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Figure 6.  Depictions of (a) the supposed binding interactions within (or 
leading to) the DAMA-colchicine:αβ-tubulin:RB3 (1SA0) crystal structure 
(ref. 24a) and (b) the proposed analogy of 1 and 39. 
 
Conformational analysis of 1 using the methodology of 
Blundell et al.51 gave a detailed view of its dynamic 3D-structure 
in dilute aqueous solution (Figure 7a).  Overlaying the resulting 
conformers of 1, in which the biaryl axis is free to assume the 
tubulin-binding (aR) configuration, and the bound colchicinoid 
38 in 1SA0 (Figure 7b) indicates that the C(3) methoxy group of 
1 coincides with the carbonyl oxygen of the (distorted) tropolone 
ring.  In an alternative comparison (Figure 7c), conformers of 1 
and a model of combretastatin A-4 6 were overlaid with the X-
ray structure of colchicine 3.52  This provides further support for 
the idea of a distinctive binding motif of 1, in which the C(4) 
hydroxy group can function as an H-bond donor in the domain 
normally occupied by the amide NH of the colchicinoid. 
(a) (b) (c)  
Figure 7.  Calculated and crystallographic models overlaid on atoms 
C(11A), C(8) and C(10) of 1.  (a) The dynamic 3D-structure of 1 in aqueous 
solution.  Carbon atoms are shown in grey and oxygen in red.  (b) The bound 
conformation of 38 from 1SA0 (residue 701, carbon atoms in grey) and the 
closest matching preferred solution conformer of 1 (carbon atoms in green) 
aligned in the same pose.  (c) The crystal structure of 3 (carbon atoms in 
grey) with the closest matching solution conformer of 1 (carbon atoms in 
green) and model of 6 (carbon atoms in pink) aligned in the same pose.  N 
atoms are shown in blue and O in red; H are omitted for clarity. 
 
The mechanistic model represented in Figure 6 should extend 
to the amine 39, which also bears a C(4)-substituent suited to the 
role of the H-bond donor in anchor a, capable of binding to the 
residue Thr179 located on the α-tubulin chain (Figure 6b).  On 
the same basis, and by analogy with ombrabulin 10, we speculate 
that a range of amides 40 derived from 39 may be potent tubulin 
binding agents, and hence potential VDAs. 
 
3. Conclusions 
In seeking new vascular disrupting agents, we evaluated the 
accessibility and biological properties of a series of substituted 
dibenz[c,e]oxepines, identifying candidate compounds by their 
ability to inhibit the growth of experimental tumour cell lines in 
vitro.  The most potent of the compounds studied was the 
benzoxepinol 1, which in the NCI-60 anticancer drug screen 
manifested broad-spectrum antiproliferative activity whose 
profile (COMPARE analysis) indicated tubulin as the biological 
target.  The results of in vivo studies confirm that the disodium 
phosphate prodrug 15, derived from 1, induces vascular 
shutdown and necrosis in DLD-1 human colon adenocarcinoma 
xenografts to an extent approaching that displayed by N-
acetylcolchinol 4, a structurally related allocolchicine derivative 
and recent drug candidate.  The phenol 1 has also been shown to 
inhibit the growth of Calu-6 lung tumour xenografts in mice at a 
dose of one-quarter of the nominal MTD. 
On the basis of the tubulin binding model shown in Figure 6, 
the large body of SAR data available for colchicinoids, and the 
characteristics of the compounds that we have prepared to date, 
we propose that the dibenz[c,e]oxepine pharmacophore offers a 
series of colchicinoid analogues with tunable tubulin binding 
characteristics.  Exploitation of the IDA strategy (Scheme 2) 
should allow rapid access to new VDAs with design features that 
would prove difficult to achieve by the modification of natural 
colchicinoids.  Amides of the form 40 are proposed as a focus for 
further development in this context. 
 
4. Experimental section 
4.1. Chemistry 
Melting points were determined using Kofler hot-stage, Buchi 
512 or Stuart Scientific SMP10 equipment and are uncorrected.  
Unless otherwise indicated, IR spectra were recorded for neat 
thin films using Perkin-Elmer 1710FT or Nicolet Nexus 670/870 
spectrometers.  NMR spectra were measured using a Bruker 
Avance III 400 spectrometer and are calibrated by reference to 
signals from the solvent (CDCl3 at 77.16 ppm and CD3OD at 
49.00 ppm for 13C spectra; residual protium in CDCl3 at 7.26 
ppm, CD3OD at 3.31 ppm and D2O at 4.79 ppm for 1H spectra).53  
Chemical shifts for 19F and 31P spectra are quoted relative to 
CFCl3 and 85% H3PO4 at 0 ppm respectively.  Coupling 
constants (J values) are given in Hz; multiplicities are given as 
singlet (s), doublet (d), triplet (t), quartet (C), quintet (qn) or 
multiplet (m).  NMR spectra were assigned with the aid of 
COSY, HMBC, HMQC and DEPT spectra where appropriate.  
Low-resolution mass spectra were recorded on a Micromass Trio 
2000 instrument using the electrospray ionisation method; data 
for peaks of intensity <20% of that of the base peak are omitted.  
High-resolution (accurate mass) data were recorded using a 
Thermo Finnigan MAT95XP instrument.  Elemental analyses 
were carried out by the University of Manchester microanalytical 
service. 
Starting materials and solvents were routinely purified by 
conventional techniques.54  Reactions were routinely carried out 
in a nitrogen atmosphere.  Tetrahydrofuran (THF) was dried 
immediately prior to use, by distillation from sodium-
benzophenone ketyl under nitrogen.  Organic solutions were 
dried using anhydrous MgSO4 and concentrated by rotary 
evaporation under reduced pressure.  Analytical thin layer 
chromatography (TLC) was carried out using Macherey-Nagel 
Polygram SIL G/UV254 plates and the chromatograms were 
routinely visualised using UV light (254 nm).  Preparative 
column (flash) chromatography was carried out on 60H silica gel 
(Merck 9385) using the flash technique.55  Compositions of 
solvent mixtures are quoted as ratios of volume.  'Petroleum' 
refers to a light petroleum fraction, b.p. 60–80 ˚C, unless 
otherwise stated.  'Ether' refers to diethyl ether.  Details of the 
preparations of 19 and 20 are provided in Supplementary 
Material. 
 
4 .1 .1 .  Improved  Ul lmann route  to  5 ,7-d ihydro-
3 ,9 ,10 ,11- te t ramethoxybenz[c ,e ]oxep in-4-o l  1  
 
4 .1 .1 .1 .  2-Formyl -6-methoxypheny l  
methanesu l fona te  (22) 5 6  
Methanesulfonyl chloride (17.76 g, 155 mmol, 12.0 mL) was 
added to a solution of o-vanillin (21.60 g, 142 mmol) in 
dichloromethane (200 mL) at 0 °C.  The mixture was left to stir 
for 5 min, then triethylamine (17.42 g, 172.2 mmol, 24.0 mL) 
was added dropwise, keeping the internal temperature at 0–5 °C.  
The mixture was stirred for a further 1 h at 0–5 ˚C and then at 
room temperature for a further 0.5 h.  The precipitate was 
collected on a Buchner funnel and rinsed with dichloromethane 
(80 mL).  The filtrate was washed with water (120 mL), aq. HCl 
(1 M; 2 x 70 mL), saturated sodium hydrogen carbonate (120 
mL) and brine (120 mL).  Drying and evaporation under reduced 
pressure gave the crude mesylate 22 (32.0 g, 98%) as a pale 
yellow oil which rapidly solidified.  Crystallisation from ethanol 
(ca. 1 mL/g) gave colourless prisms (two crops, total 26.11 g, 
80%), m.p. 78–80 ˚C (lit.56 79–80 ˚C); δH (400 MHz, CDCl3) 
3.36 (3 H, s, SO2Me), 3.95 (3 H, s, OMe), 7.26 (1 H, dd, J 8.2, 
1.6 Hz, 5-H), 7.38 (1 H, apparent dt, J ca. 8, 0.7 Hz, 4-H), 7.53 
(1 H, dd, J 7.8, 1.6 Hz, 3-H) and 10.33 (1 H, d, J 0.7 Hz, CHO); 
δC (100 MHz, CDCl3) 39.5, 56.6, 118.3, 120.5, 128.2, 131.3, 
140.3, 152.2 and 188.4; Rf 0.35 (EtOAc - hexane, 1:1); Rf 0.57 
(EtOAc - toluene, 1:9, three elutions). 
 
4 .1 .1 .2 .  3-Iodo-2- formyl -6-methoxypheny l  
methanesu l fona te  (23)  
To apply the iodination procedure described,27 the aldehyde 
22 (2.763 g, 12.0 mol) was dissolved in a warm solvent mixture 
(60 mL; from acetic acid - water - conc. sulfuric acid 100 : 10 : 3 
v/v/v).  Iodine (1.28 g, 5.04 mmol) was added, followed by 
periodic acid dihydrate (602 mg, 2.64 mmol).  The flask was 
closed with a balloon to retain vapours and the mixture was 
stirred at 60–65 ˚C for 24 h, after which time the dark mixture 
had become a clear red solution.  With continued stirring, the 
mixture was diluted with water (50 mL), decolourised by the 
portionwise addition of solid Na2S2O5 (total 500 mg), and poured 
into water (100 mL).  The resulting yellow precipitate was 
collected, washed with water and dried at the pump, giving the 
crude title compound 23 (3.71 g, 87%) which was crystallised 
from ethanol (10 mL) and dried in vacuo, giving pale yellow 
prismatic needles (3.19 g, 75%), m.p. 102–104 ˚C (Found: C, 
30.56; H, 2.48; I, 35.81; S, 8.87.  C9H9IO5S requires C, 30.35; H, 
2.55; I, 35.63; S, 9.00%); νmax/cm–1 3094, 3045, 3020, 3010, 
2941, 2912, 2887, 2841, 1702, 1588, 1563, 1467, 1437, 1390, 
1361, 1325, 1293, 1277, 1218, 1181, 1162, 1120, 1059, 971, 877, 
822, 791, 707; δH (400 MHz, CDCl3) 10.05 (1 H, s, CHO), 7.86 
(1 H, d, J 8.8 Hz, 4-H), 6.94 (1 H, d, J 8.8 Hz, 5-H), 3.93 (3 H, s, 
OMe), 3.38 (3 H, s, SMe); δC (100 MHz, CDCl3) 40.0 (CH3), 
56.8 (CH3), 85.3 (C), 118.6 (CH), 130.4 (C), 138.9 (C), 139.7 
(CH), 153.4 (C), 192.0 (CH); m/z (ES+) 411 (67%), 379 (MNa+, 
100), 374 (MH2O+, 73), 357 (MH+, 18); Rf 0.26 (EtOAc - toluene, 
1:9) [22 has Rf 0.20 under the same conditions]. 
 
4 .1 .1 .3 .  2-Iodo-3 ,4 ,5 - t r imethoxybenza ldehyde  (24)  
To apply the iodination procedure described,27 3,4,5-
trimethoxybenzaldehyde (58.86 g, 0.30 mol) was dissolved by 
warming in a mixture of acetic acid (700 mL) and 2 M sulfuric 
acid (70 mL).  Iodine (32.00 g, 126 mmol) was added, followed 
by periodic acid dihydrate (15.04 g, 66 mmol).  The flask was 
closed with a septum cap to retain vapours and the mixture was 
stirred for 4 h at 60–65 ˚C, during which the colour changed from 
opaque purple to clear orange-brown.  The stirred mixture was 
treated dropwise with a solution made by dissolving Na2S2O5 
(14.5 g, 76 mmol) in water (50 mL) and then poured into water 
(2.0 L).  The precipitated solid was collected on a Büchner 
funnel, rinsed with water, dried on the filter and then in vacuo, 
giving the aldehyde 24 (76.69 g, 79%) as a cream solid, m.p. 67–
68 ˚C [lit.25d 67 ˚C (cyclohexane)]; δH (400 MHz, CDCl3) 10.04 
(1 H, s, CHO), 7.34 (1 H, s, 6-H), 3.96 (3 H, s, OMe), 3.91 (3 H, 
s, OMe), 3.90 (3 H, s, OMe); δC (100 MHz, CDCl3) 56.4 (CH3), 
61.2 (CH3), 61.3 (CH3), 91.7 (C), 108.7 (CH), 130.7 (C), 147.9 
(C), 153.1 (C), 154.1 (C), 195.4 (CH); Rf 0.20 (EtOAc - hexane, 
1:4). 
 
4 .1 .1 .4 .  2 ,6 ' -Di formyl -4 ,2 ' ,3 ' ,4 ' -
te t ramethoxyb ipheny l-3 -y l  me thanesu l fona te  (25)  
The mesylate 23 (3.56 g, 10.0 mmol) and aldehyde 24 (9.66 g, 
30.0 mmol) were placed in a 100 mL round-bottomed flask and 
the mixture was melted by gentle heating with a hot-air gun.  
Dendritic copper powder (Aldrich 357456; 20.33 g, 0.32 mol) 
was mixed into the melt using a spatula, and the flask was then 
heated in a Woods metal bath at 185 ˚C for 20 min.  The reaction 
mixture was then allowed to cool and extracted with EtOAc (100 
mL).  The resulting suspension was filtered through a pad of 
Celite, rinsing with EtOAc, and the filtrate concentrated.  
Chromatography of the residue over silica gel (elution with 
EtOAc - hexane, gradient 1:2 to 1:1) yielded 4,4',5,5',6,6'-
hexamethoxy-1,1'-biphenyl-2,2'-dicarboxaldehyde1 followed by 
the title compound 25 (2.00 g, 47%), which formed colourless 
prisms, m.p. 132 ˚C (EtOH) [lit.1 131–132 ˚C (EtOAc)]; δH (400 
MHz, CDCl3) 10.18 (1 H, s, 2-CHO), 9.63 (1 H, s, 6'-CHO), 7.36 
(1 H, s, 5'-H), 7.26 (1 H, d, J 8.5 Hz, 6-H), 7.15 (1 H, d, J 8.5 Hz, 
5-H), 4.03 (3 H, s, OMe), 3.98 (3 H, s, OMe), 3.57 (3 H, s, 
OMe), 3.43 (3 H, s, SMe); δC (100 MHz, CDCl3) 40.0 (CH3), 
56.3 (CH3), 56.6 (CH3), 60.9 (CH3), 61.2 (CH3), 105.9 (CH), 
116.4 (CH), 127.3 (C), 129.7 (C), 130.3 (C), 130.7 (C), 132.1 
(CH), 139.5 (C), 147.3 (C), 150.8 (C), 152.3 (C), 153.8 (C), 
189.0 (CH), 190.2 (CH); Rf 0.20 (EtOAc - hexane, 2:1), 0.30 
(ether).  These data are in full accord with those published 
earlier.1  In a small-scale version of this procedure, the mesylate 
23 (356 mg, 1.0 mmol) gave the dialdehyde 25 (246 mg, 58%) as 
a colourless solid. 
 
4 .1 .1 .5 .  2 ,6 ' -B is (hydroxymethy l ) -4 ,2 ' ,3 ' ,4 ' -
te t ramethoxyb ipheny l -3 -y l  me thanesu l fona te  (26)  
Sodium borohydride (1.25 g, 33.0 mmol) was added 
portionwise to a stirred suspension of the dialdehyde 25 (6.37 g, 
15.0 mmol) in MeOH (90 mL) at room temperature.  The 
mixture, which became clear and warm, was stirred for a further 
1 h and then diluted with water (120 mL).  The bulk of the 
MeOH was removed by rotary evaporation and the residue was 
extracted with EtOAc (3 x 90 mL).  The combined extracts were 
washed with brine (90 mL), dried and evaporated.  
Crystallisation of the residue from EtOAc (20 mL) gave a semi-
solid mass that was broken up using ether (10 mL), collected on a 
filter, rinsed with EtOAc - ether (1:1) and dried in vacuo, giving 
the title compound 26 (4.54 g, 71%) as a white solid, m.p. 124–
125 ˚C (EtOAc); Rf (EtOAc - hexane 2:1) 0.18.  Concentration 
and trituration of the residue with EtOAc - ether (1:3) gave a 
further 0.80 g (12%) of the product, which was identical (1H-
NMR, 13C-NMR) to material prepared previously.1 
 
4 .1 .1 .6 .  5 ,7-Dihydro-3 ,9 ,10 ,11-
te t ramethoxybenz[c ,e] oxep in-4-y l  me thanesu l fona te  
(27)  
To a solution of 26 (4.285 g, 10.0 mmol) in acetonitrile (50 
mL) was added 48% aq. hydrobromic acid (2.5 mL, 22 mmol) 
and the solution was stirred at 50–55 ˚C for 1 h.  Water (50 mL) 
and dichloromethane (40 mL) were added, the layers were 
separated and the aqueous layer was extracted with 
dichloromethane (40 mL).  The extracts were combined, washed 
with brine (40 mL), dried and concentrated, giving the title 
compound 27 (4.035 g, 98%) as a colourless crystalline solid, 
m.p. 158–161 ˚C (MeOH), identical (TLC, 1H-NMR, 13C-NMR) 
to an authentic sample.1 
 
4 .1 .1 .7 .  5 ,7-Dihydro-3 ,9 ,10 ,11-
te t ramethoxybenz[c ,e] oxep in-4-o l  (1 )  
A solution of 27 (2.265 g, 5.52 mmol) in THF (35 mL) at 0 ˚C 
under N2 was treated dropwise with 2 M sodium 
hexamethyldisilazide in THF (5.0 mL, 10.0 mmol).29  After 5 min 
the solution was cautiously diluted with 2 M aqueous 
hydrochloric acid (12 mL) at 0 ˚C, further diluted with water (20 
mL) and extracted with EtOAc (3 x 30 mL).  The combined 
organic extracts were washed with brine (40 mL), dried and 
evaporated.  The resulting beige solid was dissolved in 
dichloromethane and the solution filtered through a short column 
of flash silica (h 4 cm, d 3 cm), eluting with dichloromethane.  
The eluate gave the title compound 1 (1.37 g, 75%) as a 
colourless solid, identical (TLC, 1H-NMR, 13C-NMR) to an 
authentic sample.1 
 
4 .1 .2 .  In tramolecular  d i rec t  ary la t ion  route  to  1  
 
4 .1 .2 .1 .  6-Bromo-3-methoxy-2-
(methoxymethoxy)benza ldehyde  (29)  
To a stirred solution of 6-bromo-2-hydroxy-3-
methoxybenzaldehyde 2857 (4.67 g, 20.2 mmol) and 
diisopropylethylamine (4.90 mL, 3.64 g, 28.1 mmol) in DMF (40 
mL) at 0 ˚C was added dropwise bromomethyl methyl ether (2.00 
mL, 3.062 g, 24.5 mmol).  After stirring at 0 ˚C for 10 min and 
then at room temperature for 1 h, the mixture was poured into 
rapidly stirring water (200 mL).  The precipitate was collected on 
a filter, washed with water (3 x 40 mL) and dried in vacuo.  To 
remove polar impurities, a solution of the crude product (5.28 g) 
in dichloromethane was filtered through a plug of silica gel (3 cm 
diameter, 6 cm depth), eluting with dichloromethane.  
Evaporation of the eluate provided the title compound 29 (5.10 g, 
92%) as a cream solid, m.p. 69–71 ˚C (EtOH) (Found: C, 43.29; 
H, 3.92; Br, 29.13.  C10H11BrO4 requires C, 43.66; H, 4.03; Br, 
29.05%); νmax/cm–1 2944, 2835, 1701, 1573, 1464, 1433, 1301, 
1258, 1157, 1064, 951; δH (400 MHz, CDCl3) 10.37 (1 H, d, J 0.5 
Hz, CHO), 7.36 (1 H, dd, J 8.8, 0.5 Hz, 5-H), 6.96 (1 H, d, J 8.8 
Hz, 5-H), 5.17 (2 H, s, OCH2O), 3.87 (3 H, s, ArOMe), 3.55 (3 
H, s, CH2OMe); δC (100 MHz, CDCl3) 56.4 (CH3), 58.1 (CH3), 
100.1 (CH2), 113.2 (C), 117.4 (CH), 129.2 (C), 129.8 (CH), 
148.9 (C), 152.5 (C), 190.8 (CH); m/z (ES+) 340/338 
(MNa2H2O+, 100%), 299/297 (MNa+, 80); Rf 0.27 (EtOAc - 
hexane, 1:3). 
 
4 .1 .2 .2 .  (6 -Bromo-3-methoxy-2-
(methoxymethoxy)pheny l )methanol  (30)  
A stirred solution of the aldehyde 29 (4.125 g, 15.0 mmol) in 
MeOH (75 mL) at room temperature was treated portionwise 
with sodium borohydride (0.76 g, 20 mmol).  The solution was 
stirred for a further 2 h and then poured into water (200 mL).  
The mixture was extracted with dichloromethane (3 x 30 mL) 
and the extract dried and concentrated.  Removal of the final 
traces of solvent in vacuo gave the title compound 30 (3.714 g, 
89%) as a colourless oil which slowly solidified.  The analytical 
sample had m.p. 60–62 ˚C (EtOAc - hexane, 1:4) (Found: C, 
43.56; H, 4.67; Br, 28.73.  C10H13BrO4 requires C, 43.34; H, 
4.73; Br, 28.83%); νmax/cm–1 3457, 2941, 2837, 1576, 1465, 
1437, 1399, 1298, 1269, 1231, 1197, 1159, 1071, 1011, 960, 924, 
799; δH (400 MHz, CDCl3) 7.31 (1 H, d, J 8.8 Hz, 4-H), 6.77 (1 
H, d, J 8.8 Hz, 5-H), 5.09 (2 H, s, OCH2O), 4.81 (2 H, s, 
ArCH2O), 3.83 (3 H, s, ArOMe), 3.59 (3 H, s, CH2OMe); δC (100 
MHz, CDCl3) 56.1 (CH3), 57.8 (CH3), 60.0 (CH2), 99.6 (CH2), 
113.2 (CH), 115.4 (C), 128.8 (CH), 134.9 (C), 146.2 (C), 151.8 
(C); m/z (ES+) 301/299 (MNa+, 100%); Rf 0.18 (EtOAc - hexane, 
1:2). 
 
4 .1 .2 .3 .  5-Bromomethy l -1 ,2 ,3 - t r imethoxybenzene  
(31) 5 8  
To a stirred solution of 3,4,5-trimethoxybenzyl alcohol (10.0 
g, 50.5 mmol) in dry dichloromethane (150 mL) under N2 at –5 
˚C was added dropwise a solution of phosphorus tribromide (3.50 
mL, 10.1 g, 37.2 mmol) in dichloromethane (10 mL).  After 
stirring at –5 ˚C for 45 min, the mixture was poured on to ice 
(200 g), neutralised with sat. aq. NaHCO3 (120 mL), and the 
organic layer was separated.  The aqueous phase was extracted 
with dichloromethane (2 x 20 mL) and the combined organic 
phases were washed with brine (30 mL), dried and concentrated 
to obtain the title compound 31 (13.0 g, 99%) as a colourless 
solid, m.p. 76–78 ˚C (hexane) [lit.58b 86–87 ˚C (petroleum)]; δH 
(400 MHz, CDCl3) 6.61 (2 H, s, 4-H and 6-H), 4.54 (2 H, s, 
CH2Br), 3.86 (6 H, s, 1-OMe and 3-OMe), 3.84 (3 H, s, 2-OMe) 
(in accord with published data43); δC (100 MHz, CDCl3) 34.4, 
56.2, 61.0, 106.2, 133.3, 138.2, 153.4. 
 
4 .1 .2 .4 .  1-Bromo-4-methoxy-3- (methoxymethoxy)-2-
( ( (3 ,4 ,5 - t r imethoxypheny l )methoxy)methy l )benzene  
(32)  
To a stirred suspension of sodium hydride (60% dispersion in 
mineral oil; 750 mg, 18.75 mmol) in THF (45 mL) under N2 at 
room temperature was added dropwise a solution of the alcohol 
30 (2.08 g, 7.5 mmol) in THF (9 mL).  After stirring at room 
temperature for 1.5 h, the mixture was treated dropwise with a 
solution of the bromide 31 (2.35 g, 9.0 mmol) in THF (9 mL) and 
the stirred mixture was heated at 45 ˚C for 2.5 h.  It was then 
poured into water (180 mL) and extracted with dichloromethane 
(3 x 60 mL).  The combined organic phases were washed with 
water (90 mL) and brine (90 mL), dried and evaporated.  
Chromatography of the residue over silica gel (elution with 
EtOAc - hexane, 1:3) gave the title compound 32 (2.95 g, 86%) 
as a colourless viscous oil (Found: M+Na+, 479.0678; 
C20H25BrO7Na requires 479.0681); νmax/cm–1 2939, 2838, 
1592, 1505, 1463, 1422, 1397, 1355, 1330, 1273, 1234, 1152, 
1128, 1101, 1072, 1008, 957, 829, 805, 780, 691; δH (400 MHz, 
CDCl3) 7.30 (1 H, d, J 8.8 Hz, 5-H), 6.77 (1 H, d, J 8.8 Hz, 6-H), 
6.65 (2 H, s, 2'-H, 6'-H), 5.10 (2 H, s, OCH2O), 4.72 (2 H, s, 
OCH2), 4.55 (2 H, s, CH2O), 3.86 (6 H, s, ArOMe), 3.822 (3 H, s, 
ArOMe), 3.818 (3 H, s, ArOMe), 3.52 (3 H, s, CH2OMe); δC (100 
MHz, CDCl3) 56.0 (CH3), 56.1 (2 x CH3), 57.7 (CH3), 60.8 
(CH3), 66.7 (CH2), 72.9 (CH2), 99.6 (CH2), 104.8 (2 x CH), 113.5 
(CH), 116.7 (CBr), 128.4 (CH), 131.6 (C), 134.2 (C), 137.3 (C), 
146.3 (C), 151.9 (C), 153.2 (2 x C); m/z (ES+) 481/479 (MNa+, 
100%); Rf 0.18 (EtOAc - hexane, 1:2). 
 
4 .1 .2 .5 .  5 ,7-Dihydro-1 ,2 ,3 ,9 - te t ramethoxy-8-
(methoxymethoxy)d ibenz[c ,e] oxep ine  (34)  
In an adaptation of the procedure described by Fagnou et al.,30 
the ether 32 (276.2 mg, 0.604 mmol), anhydrous potassium 
carbonate (powdered, 167 mg, 1.21 mmol), DavePhos 33 (23.6 
mg, 0.06 mmol) and palladium acetate (13.5 mg, 0.06 mmol) 
were placed in a round-bottomed flask.  The flask was purged 
with nitrogen for 10 min and DMA (12 mL) was added.  The 
solution was then heated, darkening above 130 ˚C to black at 145 
˚C.  TLC (EtOAc - hexane, 1:2) after 21 h at 145 ˚C suggested 
that the reaction was incomplete.  Heating was continued for 67 
h, after which the DMA was evaporated in vacuo.  The residue 
was diluted with EtOAc and the solution filtered through a plug 
of silica gel, eluting with more EtOAc.  Evaporation of the eluate 
and chromatography of the residue, eluting with acetone - hexane 
(1:4), provided the title compound 34 (127 mg, 56%) as 
colourless crystals, m.p. 112–114 ˚C (MeOH) (Found: C, 64.04; 
H, 6.47.  C20H24O7 requires C, 63.82; H, 6.43%); νmax/cm–1 
2937, 2855, 1599, 1579, 1482, 1462, 1436, 1401, 1370, 1333, 
1304, 1274, 1242, 1225, 1196, 1154, 1116, 1089, 1060, 991, 968, 
798, 734; δH (400 MHz, CDCl3) 7.43 (1 H, d, J 8.6 Hz, 1-H), 
7.00 (1 H, d, J 8.6 Hz, 2-H), 6.75 (1 H, s, 8-H), 5.22 (1 H, br d, J 
5.6 Hz, OCHO), 5.18 (1 H, br d, J 5.6 Hz, OCHO), 5.10 (1 H, d, 
J 11.2 Hz, 5-H), 4.39 (1 H, d, J 11.3 Hz, 7-H), 4.04 (1 H, d, J 
11.2 Hz, 7-H), 3.94 (3 H, s, OMe), 3.92 (3 H, s, OMe), 3.91 (3 H, 
s, OMe), 3.83 (1 H, d, J 11.2 Hz, 5-H), 3.66 (3 H, s, OMe), 3.64 
(3 H, s, OMe); δC (100 MHz, CDCl3) 56.0 (CH3), 56.2 (CH3), 
57.8 (CH3), 60.3 (CH2), 61.0 (CH3), 61.2 (CH3), 67.9 (CH2), 99.6 
(CH2), 108.8 (CH), 111.9 (CH), 125.8 (CH), 126.4 (C), 129.4 
(C), 130.5 (C), 131.1 (C), 142.7 (C), 144.0 (C), 150.7 (C), 151.6 
(C), 152.9 (C); m/z (ES+) 399 (MNa+, 100); Rf 0.21 (acetone - 
hexane, 1:4) [1 has Rf 0.16 (acetone - hexane, 1:4)]. 
 
4 .1 .2 .6 .  5 ,7-Dihydro-3 ,9 ,10 ,11-
te t ramethoxybenz[c ,e] oxep in-4-o l  (1 )  
A solution of 34 (127 mg, 0.34 mmol) in MeOH (3 mL) and 2 
M hydrochloric acid (1 mL, 2 mmol) was heated to 50–55 ˚C for 
1.5 h, after which TLC (acetone - hexane 1:3) indicated that no 
34 remained.  The solution was diluted with water (5 mL) and 
extracted with dichloromethane (3 x 5 mL).  The combined 
organic extract was washed with brine (10 mL), dried and 
evaporated.  Chromatography of the residue, eluting with hexane 
- EtOAc (2:1), gave the title compound 1 (90 mg, 80%), identical 
(TLC, 1H NMR) to that obtained from 27 as described above. 
 
4 .1 .3 .  Prepara t ive  route  to  15  
 
4 .1 .3 .1 .  5 ,7-Dihydro-3 ,9 ,10 ,11-
te t ramethoxyd ibenz[c ,e] oxep in-4-y l  
b i s (pheny lmethy l )  phosphate  (35)  
The method of Silverberg et al.33 was adapted thus:  A three-
necked flask fitted with a thermometer, nitrogen inlet and 
magnetic stirrer was charged with 1 (1.460 g, 4.39 mmol, 1.0 
eq.), N,N-dimethylaminopyridine (60 mg, 0.49 mmol, 0.11 eq.) 
and anhydrous acetonitrile (25 mL).  The resulting solution was 
cooled to an internal temperature of –10 ˚C (cooling bath of 
acetone, water and solid CO2 pellets) and treated with anhydrous 
tetrachloromethane (2.1 mL, 3.35 g, 22 mmol, 5 eq.) followed by 
diisopropylethylamine (1.6 mL, 1.19 g, 9.2 mmol, 2.1 eq.).  The 
mixture was stirred for 1 min and then treated dropwise with 
dibenzyl phosphite (1.4 mL, 1.66 g, 6.3 mmol, 1.44 eq.), keeping 
the mixture at or below –10 ˚C.  The mixture was then stirred at –
10 ˚C for a further 40 min, at which point TLC indicated the 
consumption of the organic starting materials.  The mixture was 
quenched at –10 ˚C by the dropwise addition of a solution of 
potassium dihydrogen phosphate (0.68 g) in water (10 mL), 
allowed to warm to room temperature, and then extracted with 
EtOAc (3 x 30 mL).  The combined organic phase was washed 
with water (40 mL) and brine (40 mL), dried and concentrated.  
The residue was purified by chromatography (silica gel 
preconditioned with EtOAc - hexane - Et3N 50:50:1), eluting 
with EtOAc - hexane (1:1 to 3:2), which gave the title compound 
35 (2.06 g, 79%) as a white crystalline solid, m.p. 132–133 ˚C 
(EtOH) (Found: C, 64.88; H, 5.38; P, 5.18. C32H33O9P requires C, 
64.86; H, 5.61; P, 5.23%) (M+H+, 593.1943.  C32H34O9P requires 
593.1940); νmax/cm–1 2943, 2858, 1482, 1461, 1278; δH (400 
MHz, CDCl3) 7.52 (1 H, dd, J 8.6, 1.2 Hz, 1-H), 7.40–7.29 (10 
H, m, ArH), 7.04 (1 H, d, J 8.6 Hz, 2-H), 6.75 (1 H, s, 8-H), 
5.28–5.20 (4 H, m, OCH2Ph), 5.12 (1 H, d, J 11.4 Hz, 5-H), 4.39 
(1 H, d, J 11.3 Hz, 7-H), 4.04 (1 H, d, J 11.3 Hz, 7-H), 3.95 (3 H, 
s, OMe), 3.92 (3 H, s, OMe), 3.86 (3 H, s, OMe), 3.84 (1 H, d, J 
11.4 Hz, 5-H), 3.66 (3 H, s, OMe); δC (100 MHz, CDCl3) 56.1 
(CH3), 56.2 (CH3), 60.1 (5-CH2), 61.0 (CH3), 61.2 (CH3), 67.9 
(7-CH2), 69.80 (PhCH2), 69.86 (PhCH2), 108.8 (8-CH), 112.2 (2-
CH), 125.9 (C), 127.1 (two peaks, 1-CH), 127.9 (Ph 2,6- or 3,5-
CH), 128.2 (C), 128.2 (C), 128.5 (Ph 4-H), 128.6 (Ph 2,6- or 3,5-
CH), 130.5 (C), 131.1 (C), 138.3 (C), 138.4 (C), 142.7 (C), 150.3 
(C), 150.3 (C), 150.7 (C), 153.1 (C); δP (162 MHz, CDCl3) –5.77 
(quin, J 7.5 Hz); m/z (CI, NH3) 593 (MH+, 10%); Rf 0.22 (EtOAc 
- petroleum ether 60–80˚ 1:1). 
 
4 .1 .3 .2 .  5 ,7-Dihydro-3 ,9 ,10 ,11-
te t ramethoxyd ibenz[c ,e] oxep in-4-o l  4 - (d ihydrogen  
phosphate )  (36)  
A solution of 35 (1.481 g, 2.5 mmol) in MeOH (65 mL) and 
EtOAc (10 mL) containing palladium on charcoal (10% w/w; 70 
mg) at room temperature was stirred under an atmosphere of 
hydrogen for 1 h, at which point TLC (EtOAc) indicated that the 
starting material had been consumed.  The solution was filtered 
through a pad of Celite (depth 8 mm), rinsing with MeOH, and 
evaporated.  The residue was triturated with EtOAc and the solid 
collected on filter, washed with EtOAc and dried in vacuo, giving 
the title compound 36 (984 mg, 95%) which crystallised from 
EtOH as colourless rosettes, m.p. >200 ˚C (dec.) (Found: C, 
52.36; H, 5.20; P, 7.52. C18H21O9P requires C, 52.43; H, 5.13; P, 
7.51%) (M+Na+, 435.0826.  C18H21O9PNa requires 435.0821); 
νmax/cm–1 2930, 2858, 1590, 1107; δH (400 MHz, CD3OD) 7.46 
(1 H, dd, J 8.6, 1.2 Hz, 1-H), 7.16 (1 H, d, J 8.6 Hz, 2-H), 6.89 (1 
H, s, 8-H), 5.15 (1 H, d, J 11.1 Hz, 5-H), 4.41 (1 H, d, J 11.1 Hz, 
7-H), 3.96 (1 H, d, J 11.1 Hz, 7-H), 3.93 (3 H, s, OMe), 3.91 (3 
H, s, OMe), 3.89 (3 H, s, OMe), 3.81 (1 H, d, J 11.1 Hz, 5-H), 
3.61 (3 H, s, OMe); δC (100 MHz, CD3OD) 56.5 (CH3), 56.6 
(CH3), 61.0 (5-CH2), 61.3 (CH3), 61.5 (CH3), 68.4 (7-CH2), 110.1 
(CH), 113.3 (CH), 127.3 (C), 127.8 (CH), 129.2 (C), 131.4 (C), 
132.2 (C), 140.0 (C), 140.1 (C), 144.1 (C), 151.8 (C), 152.3 (C), 
154.5 (C); δP (162 MHz, CD3OD) –4.81 (s); m/z (ES) 435 
(MNa+, 80%). 
 
4 .1 .3 .3 .  5 ,7-Dihydro-3 ,9 ,10 ,11-
te t ramethoxyd ibenz[c ,e] oxep in-4-o l  4 - (d isod ium 
phosphate )  (15)  
A stirred solution of the dihydrogen phosphate 36 (731 mg, 
1.773 mmol) in MeOH (12 mL) was treated with methanolic 
sodium methoxide (0.3984 M, 8.90 mL, 3.546 mmol) [prepared 
by dissolving freshly cut sodium (2.29 g, 99.6 mmol) in 
anhydrous MeOH (250 mL)].  The mixture was stirred for 2 min, 
then concentrated by rotary evaporation.  The residue was 
triturated with ethanol - hexane (1:1) and dried in vacuo, giving 
the title compound 15 (802 mg, 99%) as a white powder, m.p. 
208–215 ˚C (darkens above 180 ˚C) (Found: C, 45.50; H, 4.81; 
Na, 8.35; P, 6.39. C18H19Na2O9P requires C, 47.38; H, 4.20; Na, 
10.08; P, 6.79%);* (400 MHz, D2O) 7.13 (1 H, dd, J 8.6, 1.0 Hz, 
1-H), 7.05 (1 H, d, J 8.6 Hz, 2-H), 6.87 (1 H, s, 8-H), 5.29 (1 H, 
d, J 11.1 Hz, 5-H), 4.31 (1 H, d, J 11.1 Hz, 7-H), 3.84 (3 H, s, 
OMe), 3.83 (3 H, s, OMe), 3.81 (3 H, s, OMe), 3.76–3.69 (2 H, 
m, 5-H and 7-H), 3.58 (3 H, s, OMe); δC (100 MHz, D2O) 55.7 
(CH3), 56.0 (CH3), 59.9 (5-CH2), 61.1 (CH3), 61.2 (CH3), 66.5 
(7-CH2), 109.3 (CH), 112.4 (CH), 124.5 (CH), 126.3 (C), 127.8 
(C), 129.1 (C), 130.6 (C), 135.9 (C), 140.9 (C), 141.6 (C), 149.3 
(C), 151.5 (C), 152.1 (C); δP (162 MHz, D2O) –0.45 (s). 
* The elemental analysis result corresponds to a solvate with a 
w/w distribution of 15 (93.0%), water (3.7%), methanol (3.3%); 
compound 15 is hygroscopic. 
 
4 .1 .4 .  Prepara t ive  route  to  18  
 
4 .1 .4 .1 .  5 ,7-Dihydro-3 ,9 ,10 ,11-
te t ramethoxyd ibenz[c ,e] oxep in-4-y l  
t r i f luoromethanesu l fona te  (18)  
To a 5 mL flask containing the dibenzoxepinol 1 (83.2 mg, 
0.25 mmol, 1.0 eq.) and anhydrous pyridine (0.28 mL, 274 mg, 
3.46 mmol, 13.8 eq.) in dry dichloromethane (0.3 mL) under 
argon was added triflic anhydride (0.053 mL, 89 mg, 0.315 
mmol, 1.26 eq.) dropwise at 0 ˚C over a period of 2–3 min.  After 
stirring the mixture at this temperature for 30 min, TLC indicated 
the consumption of starting material.  The mixture was 
transferred to a separating funnel containing dichloromethane (2 
mL) and 1 M hydrochloric acid (2 mL).  The organic layer was 
collected and washed with more 1 M hydrochloric acid (2 x 1 
mL), saturated aqueous sodium hydrogen carbonate (1 mL) and 
brine (0.5 mL), dried and concentrated in vacuo to afford a dark 
yellow oil.  Chromatography (EtOAc - petroleum, 1:2) afforded 
the title compound 18 (90.6 mg, 78%) as a white solid, m.p. 164 
˚C (M, 464.0748.  C19H19F3O8S requires 464.0753); νmax/cm–1 
2943, 2866, 1596, 1486, 1412, 1329; δH (400 MHz, CDCl3) 3.69 
(3 H, s, OMe), 3.92 (1 H, d, J 11.5 Hz, 5-H), 3.93 (3 H, s, OMe), 
3.95 (3 H, s, OMe), 3.98 (3 H, s, OMe), 4.00 (1 H, d, J 11.5 Hz, 
7-H), 4.43 (1 H, d, J 11.5 Hz, 7-H), 4.90 (1 H, d, J 11.5 Hz, 5-H), 
6.76 (1 H, s, 8-H), 7.12 (1 H, d, J 8.7 Hz, 2-H), 7.67 (1 H, d, J 
8.7 Hz, 1-H); δC (100 MHz, CDCl3) 56.2 (CH3), 56.4 (CH3), 59.9 
(CH2), 61.1 (CH3), 61.3 (CH3), 68.0 (CH2), 98.5 (C), 99.7 (C), 
109.0 (CH), 112.5 (CH), 125.0 (C), 129.1 (C), 130.1 (CH), 131.0 
(C), 136.9 (C), 142.9 (C), 150.4 (C), 150.7 (C), 153.6 (C); δF 
(375 MHz, CDCl3) –77.98; m/z (EI) 464 (M, 10%); Rf 0.35 
(EtOAc - petroleum, 1:2). 
 
4.2. Biological Evaluation 
 
4 .2 .1 .  Inhib i t ion  o f  tubul in  assembly  and  K526  
growth  inhib i t ion  assays  
Details of the procedures are described in detail elsewhere.1 
 
4 .2 .2 .  In  v i tro  screen ing  aga ins t  NCI  ce l l  l ines  
Compounds 1 and 15–17 were submitted to the US National 
Cancer Institute (NIH, Bethesda, Maryland) for screening against 
the NCI-60 panel of human cancer cell lines, a service offered 
through the Developmental Therapeutics Program (DTP).  Full 
details of the methodology for compound testing, data analysis 
and use of the COMPARE algorithm are available on the NCI 
website.45  Compounds 1 and 15–17 were tested more than once 
in NCI-60 5-dose assays, and the average data were used in 
COMPARE analyses.  All of these were run with the GI50 values 
as the target-set endpoints and the default settings:  Minimum 
correlation 0.2; count results to return 50; minimum count 
common cell lines, 40; minimum standard deviation, 0.05.  
The test results for 1 and 15–17 were subjected to a matrix 
COMPARE analysis42 together with the colchicinoids 2–4 and 
the combretastatins 6 and 7.  In this type of analysis, the profile 
of antiproliferative activity of the 'seed' compound against the 
panel of cancer cell lines in the NCI-60 in vitro assays is 
compared with that of the 'target' compound in the same assays.  
The NSC numbers used to retrieve the data for this analysis were:  
1, NSC 756015; 15, NSC 756016; 16, NSC 756013; 17, NSC 
756014.  Data for 2–4, 6 and 7 are available in the NCI 
collection.  The results provided the source data for Tables 3a 
and 3b. 
Using the standard COMPARE protocol, the antiproliferative 
activity profiles of the 1 and 15–17 were compared with those of 
the NCI standard agents collection of anticancer agents.  For 
perspective, the analysis was also carried out with 2–4, 6 and 7 as 
the seeds.  The results provided the source data for Table 3c.  
All of the relevant data, including the complete Table 2, are 
provided in the Supplementary Material. 
 
4 .2 .3 .  In  v ivo  an t ivascu lar  e f fec t s  o f  15  
Female Balb/C immunodeficient nude mice (Harlan UK Ltd., 
Blackthorn, UK) aged 6-12 weeks were kept in cages housed in 
isolation cabinets in an air-conditioned room with regular 
alternating cycles of light and darkness.  They received Teklad 
2018 diet (Harlan) and water ad libitum.  Accurately weighed 
amounts of 15 or 21 were dissolved in sterile water and 
administered within 15 minutes of addition of solvent.  To 
determine the MTD, 15 was administered intravenously on days 
0, 2 and 4 at 200 or 400 mg kg–1 to groups of 2 mice, with a 
control group remaining untreated.  Mice were frequently 
weighed and monitored for any visible deleterious effects for 14 
d following administration.  Percentage bodyweight compared to 
bodyweight on day 0 was determined.  No major loss in 
bodyweight or other deleterious effects were observed at either of 
the concentrations of 15 administered.  A persistent reduction in 
percentage bodyweight to 85% of starting weight would be 
considered toxic.  Tumours were excised from a donor animal, 
placed in sterile physiological saline containing penicillin and 
streptomycin and cut into small fragments of approximately 
2 mm3.  Under brief general isoflurane inhalation anaesthesia, 
DLD-1 fragments were implanted in both the left and right flanks 
of each mouse using a trocar.  Once tumours had reached a 
volume of approximately 150 mm3 (as measured by callipers), to 
ensure that an established tumour vascular network was in place, 
the mice were allocated into groups of three by restricted 
randomisation to keep group mean tumour size variation to a 
minimum. 
Vascular shutdown: Seven groups of tumour-bearing mice 
(n=3 per group) were used to assess the effects of treatment with 
the compounds on the functional vasculature in DLD-1 tumours.  
Once tumours had reached a volume of approximately 150 mm3, 
to ensure that an established tumour vascular network was in 
place, mice were treated with a single 400 mg kg–1 intravenous 
dose of 15 or 21 (three groups per compound).  An untreated 
group was maintained as a control (one group).  At 1, 4 or 24 h 
following treatment (n=3 per group), vascular shutdown was 
assessed as follows: Hoechst 33342 dye was dissolved in sterile 
saline and injected intravenously by the tail vein at 40 mg kg–1.  
One minute after injection the mice in the relevant treatment 
group were sacrificed by cervical dislocation and the tumours 
carefully and rapidly excised.  One tumour from each mouse was 
then wrapped in aluminium foil, immediately immersed in liquid 
nitrogen and stored at −80 ˚C until ready for ultracryotomy.  The 
other tumour was immersion fixed in 10% neutral buffered 
formalin for 24 h and processed for paraffin embedding.  The 
control group were processed at the same time as the 24 h time-
point.  Frozen sections of 10 µm thickness were taken at 
approximately 100 µm intervals through the tumour, with each 
tumour being attributed a random number so that examination 
was done blind.  Up to five fields from each of 10 random 
sections were examined for each tumour under UV illumination 
using a Leica DMRB microscope, with images captured digitally 
through a JVC 3-CCD camera and processed using AcQuis 
(Synoptics, Cambridge, UK) software.  Functional vasculature 
was assessed by placing a cm2 grid over the captured digital 
image and counting the number of points on the grid which 
overlay fluorescently stained cells.  The percentage functional 
vasculature was then calculated by taking the total number of 
fluorescence-positive points for each field and dividing by the 
total number of points.  An average percentage for each animal 
was calculated.  Comparisons were made between percentage 
vasculature in control and treated tumours.  Statistical analysis of 
shutdown was carried out using a two-tailed Student’s t-Test.  
The results are shown in Figure 1. 
Tumour necrosis: For each animal, 5 µm thick paraffin 
sections were taken and stained with haematoxylin and eosin to 
assess for necrosis.  Each tumour was attributed a random 
number so that examination was done blind.  Digital images were 
captured using the same system as above but with bright-field 
illumination.  Percentage necrosis was assessed by placing a cm2 
grid over the captured digital image and counting the number of 
points on the grid which overlay necrotic cells.  The percentage 
necrosis was calculated by taking the total number of necrosis-
positive points for each field and dividing by the total number of 
points.  An average percentage for each animal was then 
calculated.  Statistical analysis of shutdown was carried out using 
a two-tailed Student’s t-Test.  The results are shown in Figure 2. 
See Figures 3 and 4 for sample images and Supplementary 
Material for further data. 
 
4 .2 .4 .  In  v ivo  an t i tumour  e f fec t s  o f  1  
Calu-6 human lung carcinoma cells (American Type Culture 
Collection, Manassas, VA, USA) were cultured in RPMI 
supplemented with 10% FCS and 2 mmol/L glutamine.  Cells 
were harvested in exponential phase growth and prepared at a 
concentration of 2 × 107 cells/mL in a 1:1 mix of serum-free 
RPMI and Matrigel (phenol red-free; BD Biosciences, 
Erembodegem, Belgium). 
To initiate tumour xenografts, 0.1 mL of cell suspension was 
implanted at an approximate depth of 1 mm under the skin 1 cm 
from the tail base of female nu/nu CBA mice aged 10 to 12 wk.  
Palpable tumours were evident 5–7 days after cell implantation.  
Tumour volume was measured daily using calipers.  Once a 
tumour volume of approximately 250 mm3 was attained, tumours 
were randomised into 3 treatment groups (n=6/group): vehicle 
(5% DMSO in peanut oil), compound 1 at 0.5 MTD in 5% 
DMSO/peanut oil and compound 1 at 0.25 MTD in 5% 
DMSO/peanut oil.  Compound/vehicle was administered IP at 0.1 
mL per 10 g body weight on days 1 and 5.  Mouse condition and 
body weight were monitored daily and the animals maintained 
throughout using the highest welfare standards. 
All procedures had local ethics and Home Office approval and 
were conducted under PPL 40/2328. 
 
 
4 .2 .5 .  Dynamic  3D-so lu t ion  s t ruc ture  o f  1  
Details of this analysis, which utilised the methodology of 
Blundell et al.,51 are provided in the Supplementary Material. 
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